Lastly, clinical trial pipelines are continuing to actively explore many other approaches targeting both CF genotypes abnormalities associated with no CFTR protein production and non-CFTR therapeutic pathways, which will be increasingly needed as Class I mutations (~22%) and rare CF variants are not expected to benefit from current CFTR modulators [79]. Here, CFTR is linked to cystic fibrosis.